Stroke/Brain Attack Clinical Trial
Official title:
The Tele-Taking Charge After Stroke (TeleTaCAS) Randomized Controlled Feasibility Trial of Telehealth Take Charge vs Control
Take Charge is a novel, community-based treatment for stroke developed to harness a person's self-determination. Two prior clinical trials with 572 stroke survivors showed that Take Charge improves quality of life, independence, and social participation up to a year after stroke. Take Charge has also been shown to be overall cost-saving to the health system and is a useful adjunct to standard care after stroke. Because of the COVID-19 pandemic, a lot of healthcare has moved into a telehealth approach. The simplicity of Take Charge may lend itself to being effective if delivered by telehealth, allowing greater access for people with stroke in rural communities. Improving the care we provide in underserved regions of the country is important to help the health of Canadians. We are proposing a new study, working closely with the researchers who ran the previous Take Charge studies. The goal of this feasibility clinical trial is to learn about Tele-Take Charge in adults with stroke who live in Southern Alberta. The main questions it aims to answer are: - is delivering Take Charge by telehealth feasible? - is Take Charge by telehealth acceptable to this population? Participants will meet with facilitators online via Zoom at 4 to 16 weeks after stroke, and be randomized to receive either: - two Tele-Take Charge sessions six weeks apart - one control tele-education session. Researchers will compare the Tele-Take Charge and control groups to see if there are any differences in outcome measures. these differences will help researchers to estimate the number of participants that will be needed for a larger, multi-centred effectiveness trial.
For adults diagnosed with acute stroke who are discharged to community living (non-institutionalized), we wish to evaluate whether delivering two Take Charge sessions by telehealth is (1) acceptable to the population of Southern Alberta, and (2) feasible to do. Subjects will be randomly assigned to receive either two Tele-Take Charge sessions or one tele-education session (Life After Stroke video) by telehealth (the active control). The primary feasibility outcome will be recruitment rate. Secondary outcomes will be measured by a blinded outcomes assessor at 6 and 12 months, either by e-questionnaire or by telephone. Those who received Tele-Take Charge will also be asked to complete an acceptability questionnaire, and will be invited to take part in an in-depth interview about their experience as part of a qualitative substudy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05570682 -
Manually Controlled Infusion vs Target Controlled Infusion for StrokeThrombectomy
|
N/A | |
Recruiting |
NCT04504214 -
Tendon Vibrations Effect on Upper Limb Motor Recovery After Recent Stroke
|
N/A | |
Recruiting |
NCT06179745 -
BCI Driving FES and Hand Orthosis for Upper Limb Rehabilitation in Chronic Stroke
|
N/A | |
Recruiting |
NCT04188522 -
Imaging Post-Stroke Recovery: Using MEG to Evaluate Cognition
|
||
Recruiting |
NCT06291480 -
Music Therapy After Stroke (Subacute Phase)
|
N/A | |
Active, not recruiting |
NCT06365931 -
Physiological and Functional Effects of Percutaneous Neuromodulation vs Transcutaneous Neuromodulation
|
N/A | |
Recruiting |
NCT05878457 -
Accelerated rTMS for Post-Stroke Apathy
|
Phase 1 | |
Recruiting |
NCT05657392 -
Quantitative EEG Changes Following Repetitive Transcranial Magnetic Stimulation in Patients With Post Stroke (EEG-rTMS)
|
N/A | |
Temporarily not available |
NCT05522569 -
Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)
|